• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GenHAT研究中与难治性高血压相关的遗传因素及不良健康结局关联

Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT.

作者信息

Lynch Amy I, Irvin Marguerite R, Davis Barry R, Ford Charles E, Eckfeldt John H, Arnett Donna K

机构信息

Department of Epidemiology, University of Alabama at Birmingham, RPHB 220E, 1530 3rd Avenue South, Birmingham, AL 55294-0022, USA.

出版信息

Int J Hypertens. 2013;2013:578578. doi: 10.1155/2013/578578. Epub 2013 Oct 31.

DOI:10.1155/2013/578578
PMID:24288596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3833110/
Abstract

Treatment resistant hypertension (TRH) is defined as uncontrolled hypertension (HTN) despite the use of ≥3 antihypertensive medication classes or controlled HTN while treated with ≥4 antihypertensive medication classes. Risk factors for TRH include increasing age, diminished kidney function, higher body mass index, diabetes, and African American (AA) race. Importantly, previous studies suggest a genetic role in TRH, although the genetics of TRH are largely understudied. With 2203 treatment resistant cases and 2354 treatment responsive controls (36% AA) from the Genetics of Hypertension Associated Treatment Study (GenHAT), we assessed the association of 78 candidate gene polymorphisms with TRH status using logistic regression. After stratifying by race and adjusting for potential confounders, there were 2 genetic variants in the AGT gene (rs699, rs5051) statistically significantly associated with TRH among white participants. The Met allele of rs699 and the G allele of rs5051 were positively associated with TRH: OR = 1.27 (1.12-1.44), P = 0.0001, and OR = 1.36 (1.20-1.53), P < 0.0001, respectively. There was no similar association among AA participants (race interaction P = 0.0004 for rs699 and P = 0.0001 for rs5051). This research contributes to our understanding of the genetic basis of TRH, and further genetic studies of TRH may help reach the goal of better clinical outcomes for hypertensive patients.

摘要

难治性高血压(TRH)的定义为,尽管使用了≥3类抗高血压药物但高血压仍未得到控制,或在使用≥4类抗高血压药物治疗时高血压得到控制。TRH的危险因素包括年龄增长、肾功能减退、体重指数较高、糖尿病以及非裔美国人(AA)种族。重要的是,既往研究表明基因在TRH中发挥作用,尽管TRH的遗传学在很大程度上尚未得到充分研究。利用高血压相关治疗遗传学研究(GenHAT)中的2203例难治性病例和2354例治疗反应性对照(36%为AA种族),我们采用逻辑回归评估了78个候选基因多态性与TRH状态的关联。在按种族分层并对潜在混杂因素进行校正后,AGT基因中的2个基因变异(rs699、rs5051)在白人参与者中与TRH存在统计学显著关联。rs699的Met等位基因和rs5051的G等位基因与TRH呈正相关:OR分别为1.27(1.12 - 1.44),P = 0.0001,以及OR为1.36(1.20 - 1.53),P < 0.0001。在AA参与者中未观察到类似关联(rs699的种族交互作用P = 0.0004,rs5051的种族交互作用P = 0.0001)。这项研究有助于我们理解TRH的遗传基础,TRH的进一步遗传学研究可能有助于实现改善高血压患者临床结局的目标。

相似文献

1
Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT.GenHAT研究中与难治性高血压相关的遗传因素及不良健康结局关联
Int J Hypertens. 2013;2013:578578. doi: 10.1155/2013/578578. Epub 2013 Oct 31.
2
Analysis of the Combined Effect of rs699 and rs5051 on Angiotensinogen Expression and Hypertension.rs699和rs5051对血管紧张素原表达及高血压的联合作用分析
bioRxiv. 2023 Apr 8:2023.04.07.536073. doi: 10.1101/2023.04.07.536073.
3
Analysis of the combined effect of rs699 and rs5051 on angiotensinogen expression and hypertension.rs699与rs5051对血管紧张素原表达及高血压的联合作用分析
Chronic Dis Transl Med. 2023 Dec 26;10(2):102-117. doi: 10.1002/cdt3.103. eCollection 2024 Jun.
4
Hypertension in African Populations: Review and Computational Insights.非洲人群中的高血压:综述与计算洞察。
Genes (Basel). 2021 Apr 6;12(4):532. doi: 10.3390/genes12040532.
5
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.基因面板有助于确定接受抗高血压治疗的患者中冠心病高危和低危亚组:GenHAT 研究。
Pharmacogenet Genomics. 2012 May;22(5):355-66. doi: 10.1097/FPC.0b013e3283516ff8.
6
Prevalence and determinants of apparent treatment-resistant hypertension among patients in South African primary care: a single-centre observational study.南非初级保健患者中貌似难治性高血压的患病率及影响因素:一项单中心观察性研究
BMC Cardiovasc Disord. 2025 May 19;25(1):373. doi: 10.1186/s12872-025-04813-6.
7
Association of rs5051 and rs699 polymorphisms in angiotensinogen with coronary artery disease in Iranian population: A case-control study.血管紧张素原 rs5051 和 rs699 多态性与伊朗人群冠心病的关联:病例对照研究。
Medicine (Baltimore). 2024 Mar 15;103(11):e37045. doi: 10.1097/MD.0000000000037045.
8
Cardiovascular outcome in treatment-resistant hypertension: results from the Swedish Primary Care Cardiovascular Database (SPCCD).治疗抵抗性高血压的心血管结局:来自瑞典初级保健心血管数据库(SPCCD)的结果。
J Hypertens. 2018 Feb;36(2):402-409. doi: 10.1097/HJH.0000000000001561.
9
Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study.中欧和东欧真实耐药性高血压患者的患病率和临床特征:来自 BP-CARE 研究的数据。
J Hypertens. 2013 Oct;31(10):2018-24. doi: 10.1097/HJH.0b013e328363823f.
10
Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response.收缩压多基因风险评分与氯噻酮反应的效用。
JAMA Cardiol. 2024 Dec 1;9(12):1134-1141. doi: 10.1001/jamacardio.2024.3649.

引用本文的文献

1
Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement.难治性高血压的调查与管理:英国和爱尔兰高血压学会立场声明
J Hum Hypertens. 2025 Jan;39(1):1-14. doi: 10.1038/s41371-024-00983-6. Epub 2024 Dec 9.
2
Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program.美国显性难治性高血压的特征分析:来自“我们所有人”研究计划的见解
J Am Med Inform Assoc. 2024 Dec 1;31(12):2899-2907. doi: 10.1093/jamia/ocae227.
3
The Global Burden of Resistant Hypertension and Potential Treatment Options.难治性高血压的全球负担及潜在治疗方案
Eur Cardiol. 2024 Jun 19;19:e07. doi: 10.15420/ecr.2023.51. eCollection 2024.
4
No Association Between Gene Polymorphisms with Hypertension in a South African Population.南非人群中基因多态性与高血压之间无关联。
Diabetes Metab Syndr Obes. 2024 Apr 29;17:1853-1865. doi: 10.2147/DMSO.S452272. eCollection 2024.
5
Whole genome sequence analysis of apparent treatment resistant hypertension status in participants from the Trans-Omics for Precision Medicine program.精准医学跨组学计划参与者中明显治疗抵抗性高血压状态的全基因组序列分析。
Front Genet. 2023 Dec 13;14:1278215. doi: 10.3389/fgene.2023.1278215. eCollection 2023.
6
When blood pressure refuses to budge: exploring the complexity of resistant hypertension.当血压顽固不降时:探索顽固性高血压的复杂性。
Front Cardiovasc Med. 2023 Jun 21;10:1211199. doi: 10.3389/fcvm.2023.1211199. eCollection 2023.
7
Excessive dietary sodium intake and elevated blood pressure: a review of current prevention and management strategies and the emerging role of pharmaconutrigenetics.过量膳食钠摄入与血压升高:当前预防和管理策略综述以及药物营养遗传学的新作用
BMJ Nutr Prev Health. 2018 Sep 19;1(1):7-16. doi: 10.1136/bmjnph-2018-000004. eCollection 2018.
8
Optimizing identification of resistant hypertension: Computable phenotype development and validation.优化耐药性高血压的识别:可计算表型的开发和验证。
Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1393-1401. doi: 10.1002/pds.5095. Epub 2020 Aug 26.
9
Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group.全基因组关联研究明显治疗抵抗性高血压在 CHARGE 联盟:CHARGE 遗传药理学工作组。
Am J Hypertens. 2019 Nov 15;32(12):1146-1153. doi: 10.1093/ajh/hpz150.
10
Natural selection and local adaptation of blood pressure regulation and their perspectives on precision medicine in hypertension.血压调节的自然选择与局部适应性及其对高血压精准医学的启示
Hereditas. 2019 Jan 7;156:1. doi: 10.1186/s41065-019-0080-1. eCollection 2019.

本文引用的文献

1
Renal sympathetic denervation for treatment of resistant hypertension: a systematic review.肾去交感神经术治疗耐药性高血压:系统评价。
J Clin Hypertens (Greenwich). 2013 Jan;15(1):75-84. doi: 10.1111/jch.12027. Epub 2012 Oct 26.
2
Hyperaldosteronism as a common cause of resistant hypertension.醛固酮增多症是难治性高血压的常见病因。
Annu Rev Med. 2013;64:233-47. doi: 10.1146/annurev-med-042711-135929. Epub 2012 Oct 22.
3
Association between the M235T polymorphism of the AGT gene and cytokines in patients with hypertension.高血压患者AGT基因M235T多态性与细胞因子之间的关联
Exp Ther Med. 2012 Mar;3(3):509-512. doi: 10.3892/etm.2011.433. Epub 2011 Dec 23.
4
Lack of association of A-6G polymorphism of AGT gene with essential hypertension in the Chinese population.血管紧张素原基因 AGT 中的 A-6G 多态性与中国人原发性高血压无关。
J Cardiovasc Med (Hagerstown). 2012 Aug;13(8):505-10. doi: 10.2459/JCM.0b013e328355a726.
5
Resistant hypertension: incidence, prevalence, and prognosis.顽固性高血压:发病率、患病率及预后
Circulation. 2012 Apr 3;125(13):1594-6. doi: 10.1161/CIRCULATIONAHA.112.097345. Epub 2012 Feb 29.
6
Digging into the extremes: a useful approach for the analysis of rare variants with continuous traits?深入研究极端情况:一种分析具有连续性状的罕见变异的有用方法?
BMC Proc. 2011 Nov 29;5 Suppl 9(Suppl 9):S105. doi: 10.1186/1753-6561-5-S9-S105.
7
Association of polymorphisms in the AGT gene with essential hypertension in the Chinese population.中国人血管紧张素原基因多态性与原发性高血压的相关性研究。
J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):282-8. doi: 10.1177/1470320311430991. Epub 2011 Dec 12.
8
Gender-related association of AGT gene variants (M235T and T174M) with essential hypertension--a case-control study.AGT 基因变异(M235T 和 T174M)与原发性高血压的性别相关性——一项病例对照研究。
Clin Exp Hypertens. 2012;34(1):38-44. doi: 10.3109/10641963.2011.618207. Epub 2011 Dec 9.
9
Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008.美国 1988 年至 2008 年期间不受控制且明显的治疗抵抗性高血压。
Circulation. 2011 Aug 30;124(9):1046-58. doi: 10.1161/CIRCULATIONAHA.111.030189. Epub 2011 Aug 8.
10
Strategic approaches to unraveling genetic causes of cardiovascular diseases.解析心血管疾病遗传病因的策略方法。
Circ Res. 2011 May 13;108(10):1252-69. doi: 10.1161/CIRCRESAHA.110.236067.